Otonomy Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
04 mars 2019 16h18 HE
|
Otonomy, Inc.
OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for results in first half 2020 OTO-313 Phase 1/2 trial in tinnitus expected to start in second quarter of 2019OTO-413 Phase 1/2 trial in hearing...
Otonomy to Report Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update
25 févr. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
06 févr. 2019 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
Otonomy Provides Corporate and Product Pipeline Update
03 janv. 2019 07h30 HE
|
Otonomy, Inc.
Three programs with clinical trial results in 2020 including OTIVIDEX™ Phase 3 trial in Ménière’s disease Current capital funds operations into 2021 SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) --...
Otonomy to Present at the J.P. Morgan Healthcare Conference
02 janv. 2019 16h05 HE
|
Otonomy, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
15 nov. 2018 08h30 HE
|
Otonomy, Inc.
SAN DIEGO, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David...
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
06 nov. 2018 07h30 HE
|
Otonomy, Inc.
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company...
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
05 nov. 2018 16h12 HE
|
Otonomy, Inc.
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO, Nov. 05, 2018...
Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"
30 oct. 2018 07h30 HE
|
Otonomy, Inc.
SAN DIEGO, Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple...
Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update
29 oct. 2018 07h30 HE
|
Otonomy, Inc.
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the...